CurrentUnitedHealthcarePolicy N/A

Amlodipine/valsartan/hydrochlorothiazide (generic Exforge HCT) prior authorization

Sets prior authorization and reauthorization requirements for coverage of the generic triple antihypertensive combination amlodipine/valsartan/hydrochlorothiazide for UnitedHealthcare members.

Policy Summary

PayerUnitedHealthcare

PolicyAmlodipine/valsartan/hydrochlorothiazide (generic Exforge HCT) prior authorization

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateDec 1, 2025

Next Review DateOct 1, 2025

Key ActionSubmit prior authorization with documentation of therapeutic failure on concomitant amlodipine/valsartan and hydrochlorothiazide and prescriber rationale that the patient cannot adhere to separate agents.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

12 monthsauthorization duration

Prior Authprogram type

Brand excludedbrand coverage note

through 10/2025last P&T approval

Coverage Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

inv-01: Initial Therapy

Covered when ALL of the following are met:

Initial Authorization: 1. Patient has a history of a trial resulting in therapeutic failure (blood pressure goal not met) to BOTH taken concomitantly: (i) amlodipine/valsartan (generic Exforge) AND (ii) hydrochlorothiazide.

From Initial Authorization; [[chunk 2]]

Adherence/Prescriber Determination: 2. Patient is unable to adhere to antihypertensive therapy and prescriber determines combination therapy would be beneficial.

From Initial Authorization continuation; [[chunk 3]]

Initial Therapy Criteria

inv-10: Initial Therapy

Initial authorization requirements

Prior trial of components: Documented therapeutic failure on concomitant amlodipine/valsartan AND hydrochlorothiazide (therapeutic failure = blood pressure goal not met).

Initial Authorization section; [[chunk 2]]

Prescriber attestation: Prescriber documents that the patient is unable to adhere to separate antihypertensive agents and that combination therapy would be beneficial.

Initial Authorization continuation; [[chunk 3]]

Continuation / Reauthorization Criteria

inv-11: Reauthorization

Reauthorization rules

Clinical response: Documentation of positive clinical response to therapy is required for reauthorization.

Reauthorization criterion; [[chunk 4]]

Authorization period: Authorize renewal for 12 months (subject to state mandates and member benefit plan).12 months

Authorization duration; [[chunk 5]]

Provider Actions and Requirements

Prior Authorization

Prior Authorization Required

Prior authorization required. Initial approval requires documented therapeutic failure with the individual components taken concomitantly and prescriber determination that combination therapy is needed due to inability to adhere to separate agents.

Affected product: amlodipine/valsartan/hydrochlorothiazide (generic Exforge HCT)
Initial requirement: documented trial with concomitant amlodipine/valsartan (generic Exforge) and hydrochlorothiazide showing therapeutic failure (blood pressure goal not met)

Step Therapy

Step Requirement — Trial of Concomitant Components

Coverage is contingent on completing the step requirement of prior use of the individual component products taken concomitantly (a trial of the separate components is required before approval of the fixed‑dose combination).

Step therapy: trial of concomitant amlodipine/valsartan plus hydrochlorothiazide prior to approval

Documentation Required

Documentation Required for Initial and Continued Coverage

Documentation is required for both initial and continued coverage. Initial requests must include evidence of prior trial failure on concomitant amlodipine/valsartan and hydrochlorothiazide. Reauthorization requires documentation of a positive clinical response to the combination therapy.

Initial documentation: clinical record showing therapeutic failure (BP goal not met) on concomitant amlodipine/valsartan and hydrochlorothiazide
Reauthorization documentation: evidence of positive clinical response while on amlodipine/valsartan/hydrochlorothiazide

Denial Risk

Denial Triggers — Missing Required Documentation

Requests lacking the required prior‑trial or response documentation will be denied. Specifically, absence of documentation showing therapeutic failure on concomitant amlodipine/valsartan (Exforge) plus hydrochlorothiazide, or lack of prescriber rationale that combination therapy is needed due to inability to adhere to separate agents, are denial triggers.

Denial triggers: no documentation of prior therapeutic failure on the concomitant components
Denial triggers: no prescriber statement that patient cannot adhere to separate antihypertensive agents
Denial triggers for reauthorization: no documentation of positive clinical response

Step	Requirement	Failure definition	Step number
Trial of concomitant individual components (amlodipine/valsartan and hydrochlorothiazide)	Patient must have a history of a trial resulting in therapeutic failure to both agents when taken concomitantly (amlodipine/valsartan and hydrochlorothiazide)	Therapeutic failure defined as blood pressure goal not met on concomitant therapy	1

Background

Combination antihypertensive pills can improve adherence for patients who have difficulty taking multiple individual agents. This program permits coverage of the generic triple combination amlodipine/valsartan/hydrochlorothiazide for members who either have not achieved blood pressure goals on separate concomitant agents or who are unable to adhere to multiple separate medications.

When authorized, coverage for the generic product is issued for 12 months; state mandates, federal requirements, and the member's benefit plan may affect coverage.

Definitions

inv-09: Therapeutic failure — Blood pressure goal not met despite use of the specified concomitant therapies.

DefinitionBlood pressure goal not met despite use of the specified concomitant therapies (therapeutic failure).

ContextUsed to document lack of adequate response to separate component therapy prior to approving fixed‑dose triple combination (amlodipine/valsartan/hydrochlorothiazide).

Evidence requiredClinical documentation showing that blood pressure targets were not achieved while the patient was taking concomitant amlodipine/valsartan and hydrochlorothiazide.

Relation to coverageTherapeutic failure is a required criterion for initial authorization of the triple combination product.

Implication for step therapyDefines failure criteria for the step requiring trial of the individual component products taken concomitantly before approving the fixed‑dose triple product.